Cancer Cytopathology最新文献

筛选
英文 中文
The World Health Organization Reporting System for Pancreaticobiliary Cytopathology: Overview and Summary 世界卫生组织胰胆细胞病理学报告系统:概述和总结。
IF 2.6 3区 医学
Cancer Cytopathology Pub Date : 2024-05-06 DOI: 10.1002/cncy.22806
Barbara A. Centeno MD, Mauro Saieg MD, PhD, Momin T. Siddiqui MD, Miguel Perez-Machado MD, PhD, Lester J. Layfield MD, Birgit Weynand, Michelle D. Reid MD, Edward B. Stelow MD, Maria D. Lozano MD, PhD, Noriyoshi Fukushima MD, PhD, Ian A. Cree, Ravi Mehrotra MD, Fernando C. Schmitt MD, PhD, Andrew S. Field MBBS (Hons), Martha B. Pitman MD
{"title":"The World Health Organization Reporting System for Pancreaticobiliary Cytopathology: Overview and Summary","authors":"Barbara A. Centeno MD,&nbsp;Mauro Saieg MD, PhD,&nbsp;Momin T. Siddiqui MD,&nbsp;Miguel Perez-Machado MD, PhD,&nbsp;Lester J. Layfield MD,&nbsp;Birgit Weynand,&nbsp;Michelle D. Reid MD,&nbsp;Edward B. Stelow MD,&nbsp;Maria D. Lozano MD, PhD,&nbsp;Noriyoshi Fukushima MD, PhD,&nbsp;Ian A. Cree,&nbsp;Ravi Mehrotra MD,&nbsp;Fernando C. Schmitt MD, PhD,&nbsp;Andrew S. Field MBBS (Hons),&nbsp;Martha B. Pitman MD","doi":"10.1002/cncy.22806","DOIUrl":"10.1002/cncy.22806","url":null,"abstract":"<p>The recently published <i>WHO Reporting System for Pancreaticobiliary Cytopathology</i> (World Health Organization [WHO] System) is an international approach to the standardized reporting of pancreaticobiliary cytopathology, updating the <i>Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology</i> (PSC System). Significant changes were made to the categorization of benign neoplasms, intraductal neoplasms, mucinous cystic neoplasms, and malignant neoplasms considered low grade. Benign neoplasms, such as serous cystadenoma, categorized as Neoplastic: benign in the PSC system, are categorized as Benign/negative for malignancy in the WHO system. Pancreatic neuroendocrine tumor, solid-pseudopapillary neoplasm, and gastrointestinal stromal tumor, categorized as Neoplastic: other in the PSC system, are categorized as Malignant in the WHO System in accord with their classification in the 5th edition WHO Classification of Digestive System Tumours (2019). The two new categories of Pancreaticobiliary Neoplasm Low-risk/grade and Pancreaticobiliary Neoplasm High-risk/grade are mostly limited to intraductal neoplasms and mucinous cystic neoplasms. Low-risk/grade lesions are mucinous cysts, with or without low-grade epithelial atypia. High-risk/grade lesions contain neoplastic epithelium with high-grade epithelial atypia. Correlation with clinical, imaging, and ancillary studies remains a key tenet. The sections for each entity are written to highlight key cytopathological features and cytopathological differential diagnoses with the pathologist working in low resource setting in mind. Each section also includes the most pertinent ancillary studies useful for the differential diagnosis. Sample reports are provided for each category. Finally, the book provides a separate section with risk of malignancy and management recommendations for each category to facilitate decision-making for clinicians.</p>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 7","pages":"396-418"},"PeriodicalIF":2.6,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22806","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Climate change is threatening access to cancer care 气候变化正威胁着癌症护理的可及性
IF 3.4 3区 医学
Cancer Cytopathology Pub Date : 2024-05-01 DOI: 10.1002/cncy.22828
Bryn Nelson PhD, William Faquin MD, PhD
{"title":"Climate change is threatening access to cancer care","authors":"Bryn Nelson PhD,&nbsp;William Faquin MD, PhD","doi":"10.1002/cncy.22828","DOIUrl":"https://doi.org/10.1002/cncy.22828","url":null,"abstract":"&lt;p&gt;After a natural disaster, the danger is far from over for residents with health concerns, whether cancer or other conditions. An extreme event may disrupt access to shelter, food, and water while also destroying medications, health supplies, roads, and health care facilities. Because power and telecommunications are often knocked out, telehealth can be difficult or impossible.&lt;/p&gt;&lt;p&gt;Extreme events are not new hazards. With a hotter planet fueling stronger and more unpredictable storms, flooding, wildfires, and heatwaves, however, researchers are having to rethink how they approach disaster preparedness and response and risk communication for increasingly vulnerable communities. “The same people who are at risk of flooding also may live in a fenceline community where the flooding could cause the redistribution of chemical contaminants that could also impact their health,” says Jennifer Horney, PhD, a professor of epidemiology at the University of Delaware in Newark.&lt;/p&gt;&lt;p&gt;That dual risk was laid bare by the 2017 flooding of the heavily industrialized Houston Ship Canal and surrounding neighborhoods by Hurricane Harvey, says Dr Horney, a core faculty member of the University of Delaware’s Disaster Research Center. Access, safety concerns, and other pressure points can likewise be magnified by extreme events. “If you have housing that’s not safe or a lack of transportation, those things are really important in non-disaster times to your health, but they’re really, &lt;i&gt;really&lt;/i&gt; important in disaster times,” Dr Horney says.&lt;/p&gt;&lt;p&gt;For patients with cancer, the need for specialized care can compound the threat. “When you think about it in the context of access to care and extreme weather events disrupting that access, access to cancer care is really critical,” says Eva Rawlings Parker, MD, assistant professor of dermatology at Vanderbilt University Medical Center in Nashville, Tennessee. “It’s one thing if you miss your routine physical and can reschedule that. It’s quite another thing if you miss your chemotherapy infusion: It can have much more significant consequences.”&lt;/p&gt;&lt;p&gt;A 2019 study led by researchers at the American Cancer Society found that hurricane disasters were associated with worse overall survival for patients with locally advanced non–small cell lung cancer who were undergoing daily radiotherapy.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The longer the disaster declaration was, the worse their survival was, for disasters lasting up to a month. Because even short radiotherapy delays can decrease lung cancer survival rates, the authors recommended that disaster mitigation planning include strategies for identifying at-risk patients with cancer, arranging for their transfer to other treatment centers, and eliminating out-of-network insurance charges.&lt;/p&gt;&lt;p&gt;The growing urgency to develop contingency plans could be aided by lessons learned from vulnerable facilities and populations, notes Leticia Nogueira, PhD, MPH, scientific director of health service","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 5","pages":"266-267"},"PeriodicalIF":3.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22828","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140817269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is molecular testing of salivary gland FNA specimens ready for prime time? 唾液腺 FNA 标本的分子检测是否已准备就绪?
IF 2.6 3区 医学
Cancer Cytopathology Pub Date : 2024-04-29 DOI: 10.1002/cncy.22825
Marc P. Pusztaszeri MD
{"title":"Is molecular testing of salivary gland FNA specimens ready for prime time?","authors":"Marc P. Pusztaszeri MD","doi":"10.1002/cncy.22825","DOIUrl":"10.1002/cncy.22825","url":null,"abstract":"","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 7","pages":"393-395"},"PeriodicalIF":2.6,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140810875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy of International System for Reporting Serous Fluid Cytopathology: A systematic review and meta-analysis in malignancy diagnosis 国际浆液细胞病理学报告系统的诊断准确性:恶性肿瘤诊断的系统回顾和荟萃分析
IF 2.6 3区 医学
Cancer Cytopathology Pub Date : 2024-04-13 DOI: 10.1002/cncy.22822
Sana Ahuja MD, Rhea Ahuja MD, Shivam Pandey PhD, Sufian Zaheer MD
{"title":"Diagnostic accuracy of International System for Reporting Serous Fluid Cytopathology: A systematic review and meta-analysis in malignancy diagnosis","authors":"Sana Ahuja MD,&nbsp;Rhea Ahuja MD,&nbsp;Shivam Pandey PhD,&nbsp;Sufian Zaheer MD","doi":"10.1002/cncy.22822","DOIUrl":"10.1002/cncy.22822","url":null,"abstract":"<p>This study conducts the first meta-analysis to assess the aggregated risk of malignancy associated with each category of the International System for Reporting Serous Fluid Cytopathology (ISRSFC) for reporting serous effusion cytology, while also evaluating diagnostic accuracy. PubMed/MEDLINE and Embase were systematically searched using the keywords “(pleural, peritoneal, and pericardial effusions) AND (serous effusion cytology) OR (International System for Reporting Serous Fluid Cytopathology)”. Articles underwent risk of bias assessment using the QUADAS-2 tool. After excluding inadequate samples, a meta-analysis determined sensitivity and specificity for different cutoff points, including \"atypical considered positive,\" \"suspicious of malignancy considered positive,\" and \"malignant considered positive.\" Summary receiver operating characteristic curves assessed diagnostic accuracy, and the diagnostic odds ratio was pooled. Sixteen retrospective cross-sectional studies, totaling 19,128 cases, were included. Sensitivity and specificity for the “atypical and higher risk categories” considered positive were 77% (95% confidence interval [CI], 68%–84%) and 95% (95% CI, 93%–97%) respectively. For the “suspicious for malignancy and higher risk categories” considered positive, sensitivity and specificity were 57% (95% CI, 49%–65%) and 100% (95% CI, 99%–100%) respectively. Sensitivity and specificity for the “malignant” category considered positive for malignancy were 70% (95% CI, 60%–77%) and 99% (95% CI, 98%–99%), respectively. The pooled area under the curve ranged from 85% to 89.5% for each cutoff. This meta-analysis underscores the ISRSFC's accuracy in reporting serous fluid cytology. It emphasizes the diagnostic importance of the \"suspicious\" and \"malignant\" categories in identifying malignancy, and the role of the \"benign\" category in ruling out malignancy.</p>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 10","pages":"609-620"},"PeriodicalIF":2.6,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140570096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical squamous cells in urine cytology are associated with a significant risk of high-grade malignancy 尿液细胞学检查中的非典型鳞状细胞与高级别恶性肿瘤的重大风险有关
IF 2.6 3区 医学
Cancer Cytopathology Pub Date : 2024-04-13 DOI: 10.1002/cncy.22816
Linh Ho MD, Tarik M. Elsheikh MD
{"title":"Atypical squamous cells in urine cytology are associated with a significant risk of high-grade malignancy","authors":"Linh Ho MD,&nbsp;Tarik M. Elsheikh MD","doi":"10.1002/cncy.22816","DOIUrl":"10.1002/cncy.22816","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Atypical squamous cells (ASC) in urine cytology are rarely found, and their clinical significance is not well studied. Previous studies were limited by a small number of cases and a lack of objective grading of ASC and/or their correlation with accompanying urothelial cell abnormality (UCA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The institutional database was searched over 10 years for urine cytology reports containing ASC or from patients who had a concurrent diagnoses of high-grade (HG) urothelial carcinoma with squamous differentiation or squamous carcinoma. ASC were defined as keratinized squamous cells and were subcategorized as reactive, koilocytosis, low-grade (LG) atypia, and HG atypia. Correlations with age, sex, specimen type, accompanying UCA, number of ASC, and the risk of HG malignancy (ROHM) were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ASC were present in 0.15% of all urine specimens (123 of 81,018). Slides and clinical follow-up were available on 91 patients (median age, 71 years). LG and HG squamous atypia had ROHMs of 70% and 92%, respectively. ASC not accompanied and accompanied by UCA had ROHMs of 37% and 94%, respectively. Most malignancies (34 of 67; 51%) showed rare ASC in urine. Reactive changes and koilocytosis had 0% ROHM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>ASC in urine cytology is a significant finding and is associated with a high ROHM. In the absence of accompanying UCA, LG squamous atypia had a lower ROHM than HG atypia. In the presence of UCA, LG and HG squamous atypia had ROHMs of over 90%. These findings suggest that ASC and their grade of atypia should be noted in the cytology report, and clinicians should be made aware of their clinical significance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 8","pages":"499-509"},"PeriodicalIF":2.6,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22816","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140570008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spotlight: Rising stars in cytology 聚焦:细胞学新星
IF 2.6 3区 医学
Cancer Cytopathology Pub Date : 2024-04-11 DOI: 10.1002/cncy.22823
Pasquale Pisapia MD, PhD
{"title":"Spotlight: Rising stars in cytology","authors":"Pasquale Pisapia MD, PhD","doi":"10.1002/cncy.22823","DOIUrl":"10.1002/cncy.22823","url":null,"abstract":"","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 8","pages":"465-466"},"PeriodicalIF":2.6,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140569997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How the Milan System for Reporting Salivary Gland Cytopathology works in cytopathology practice: Meta-analysis of prospective studies and comparison with retrospective studies 米兰唾液腺细胞病理学报告系统如何在细胞病理学实践中发挥作用:前瞻性研究的元分析以及与回顾性研究的比较
IF 2.6 3区 医学
Cancer Cytopathology Pub Date : 2024-04-09 DOI: 10.1002/cncy.22815
Henri Lagerstam BMed, David Kalfert MD, PhD, Zahra Maleki MD, MIAC, Ivana Kholová MD, PhD, MIAC
{"title":"How the Milan System for Reporting Salivary Gland Cytopathology works in cytopathology practice: Meta-analysis of prospective studies and comparison with retrospective studies","authors":"Henri Lagerstam BMed,&nbsp;David Kalfert MD, PhD,&nbsp;Zahra Maleki MD, MIAC,&nbsp;Ivana Kholová MD, PhD, MIAC","doi":"10.1002/cncy.22815","DOIUrl":"10.1002/cncy.22815","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is widely accepted and endorsed by professional societies. Although several studies focusing on the MSRSGC have been published, few have been prospective studies. The objective of this study was to evaluate the effectiveness of the MSRSGC in cytopathology practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive literature search was conducted to identify all prospective studies on the MSRSGC. The risk of malignancy (ROM), risk of neoplasm, and diagnostic accuracy for each diagnostic category were calculated. Data were tabulated in Microsoft Excel, and analyses were performed with the Open Meta-Analyst program.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seven prospective and seven retrospective studies were identified. The total number of fine-needle aspirations (FNAs) was 1587 in the prospective studies and 1764 in the retrospective studies. The ROM values for the nondiagnostic, nonneoplastic, atypia of undetermined significance, benign neoplasm, salivary gland neoplasm of uncertain malignant potential, suspicious for malignancy, and malignant categories in prospective versus retrospective studies were 21.0% versus 26.6%, 9.4% versus 8.1%, 34.9% versus 39.6%, 2.4% versus 2.1%, 36.6% versus 31.2%, 86.0% versus 66.0%, and 97.0% versus 96.7%, respectively. Sensitivities, specificities, and diagnostic odds ratios were 83.1% (95% confidence interval [CI], 71.1%–90.8%) versus 89.1% (95% CI, 83.6%–92.9%), 98.4% (95% CI, 96.6%–99.3%) versus 94.9% (95% CI, 91.9%–96.9%), and 310.7 (95% CI, 121.2–796.6) versus 218.8 (95% CI, 107.3–438.1).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This meta-analysis indicated that the MSRSGC works well in FNA cytopathology practice and improves diagnostic accuracy in all diagnostic categories. The ROMs of prospective studies were in concordance with the MSRSGC reference values.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 7","pages":"447-457"},"PeriodicalIF":2.6,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22815","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140570000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology 探索意义未定的不典型性:将恶性比率、ThyroSeq v3 阳性调用率、分子衍生恶性风险和恶性风险作为甲状腺细胞学的可能质量度量工具
IF 2.6 3区 医学
Cancer Cytopathology Pub Date : 2024-04-09 DOI: 10.1002/cncy.22820
Jaylou M. Velez Torres MD, Porshya M. Curnow CT, ASCP, Youley Tjendra MD, Merce Jorda MD, Carmen Gomez Fernandez MD, Monica Garcia Buitrago MD, Yiqin Zuo MD, Roberto Ruiz Cordero MD
{"title":"Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology","authors":"Jaylou M. Velez Torres MD,&nbsp;Porshya M. Curnow CT, ASCP,&nbsp;Youley Tjendra MD,&nbsp;Merce Jorda MD,&nbsp;Carmen Gomez Fernandez MD,&nbsp;Monica Garcia Buitrago MD,&nbsp;Yiqin Zuo MD,&nbsp;Roberto Ruiz Cordero MD","doi":"10.1002/cncy.22820","DOIUrl":"10.1002/cncy.22820","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The atypia of undetermined significance (AUS) category is heterogeneous, leading to variations in its use. To prevent excessive usage, the AUS rate should be ≤10%. Although this recommendation aims to maintain diagnostic quality, it lacks supporting data. The AUS:Malignant (AUS:M) ratio has been proposed as a metric tool to evaluate AUS use. Furthermore, integrating ThyroSeq v3 (TSV3) positive call rate (PCR) and the molecular-derived risk of malignancy (MDROM) have been put forward as performance improvement tools. The authors reviewed their AUS:M ratios, TSV3 PCR, MDROM, and ROM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Thyroid aspirates evaluated in the laboratory (from August 2022 to September 2023) by seven cytopathologists (CPs) were identified. AUS:M ratio, MDROM, ROM, and TSV3 PCR results for the laboratory and each CP were recorded and analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 2248 aspirates were identified (462 AUS and 80 malignant). The AUS:M ratio for the laboratory was 5.8 (CPs range, 2.8 to 7.3). The TSV3 PCR for the laboratory was 23% (CPs range, 11% to 41%). The MDROM for the laboratory was 19% (CPs range, 9% to 31%), whereas the ROM was 36% (CPs range, 29% to 50%). Linear regression analysis of AUS:M ratio versus TSV3 PCR and MDROM demonstrated a moderate positive correlation but a weak negative correlation to the ROM. Deviations from established targets were attributed to multiple factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The findings of this study underscore the importance of using a combination of metrics to evaluate diagnostic practices. By dissecting the practice patterns of each CP, the authors can measure different aspects of their performance and provide individualized feedback.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 8","pages":"491-498"},"PeriodicalIF":2.6,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22820","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140602952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypia of undetermined significance and ThyroSeq v3–positive call rates as quality control metrics for cytology laboratory performance 将意义未定的不典型性和 ThyroSeq v3 阳性调用率作为细胞学实验室绩效的质量控制指标
IF 2.6 3区 医学
Cancer Cytopathology Pub Date : 2024-04-09 DOI: 10.1002/cncy.22821
Odille Mejia-Mejia MD, Andres Bravo-Gonzalez MD, Monica Sanchez-Avila MD, Youley Tjendra MD, Rodrigo Santoscoy MD, Katherine Drews-Elger MD PhD, Yiqin Zuo MD PhD, Camilo Arias-Abad PhD, Carmen Gomez MD, Monica Garcia-Buitrago MD, Mehrdad Nadji MD, Merce Jorda MD PhD MBA, Jaylou M. Velez-Torres MD, Roberto Ruiz-Cordero MD
{"title":"Atypia of undetermined significance and ThyroSeq v3–positive call rates as quality control metrics for cytology laboratory performance","authors":"Odille Mejia-Mejia MD,&nbsp;Andres Bravo-Gonzalez MD,&nbsp;Monica Sanchez-Avila MD,&nbsp;Youley Tjendra MD,&nbsp;Rodrigo Santoscoy MD,&nbsp;Katherine Drews-Elger MD PhD,&nbsp;Yiqin Zuo MD PhD,&nbsp;Camilo Arias-Abad PhD,&nbsp;Carmen Gomez MD,&nbsp;Monica Garcia-Buitrago MD,&nbsp;Mehrdad Nadji MD,&nbsp;Merce Jorda MD PhD MBA,&nbsp;Jaylou M. Velez-Torres MD,&nbsp;Roberto Ruiz-Cordero MD","doi":"10.1002/cncy.22821","DOIUrl":"10.1002/cncy.22821","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) recommends an upper limit of 10% for atypia of undetermined significance (AUS). Recent data suggest that this category might be overused when the rate of cases with molecular positive results is low. As a quality metric, the AUS and positive call rates for this facility’s cytology laboratory and each cytopathologist (CP) were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis of all thyroid cytology cases in a 4.5-year period was performed. Cases were stratified by TBSRTC, and molecular testing results were collected for indeterminate categories. The AUS rate was calculated for each CP and the laboratory. The molecular positive call rate (PCR) was calculated with and without the addition of currently negative to the positive results obtained from the ThyroSeq report.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 7535 cases were classified as nondiagnostic, 7.6%; benign, 69%; AUS, 17.5%; follicular neoplasm/suspicious for follicular neoplasm, 1.4%; suspicious for malignancy, 0.7%; and malignant, 3.8%. The AUS rate for each CP ranged from 9.9% to 36.8%. The overall PCR was 24% (range, 13%–35.6% per CP). When including cases with currently negative results, the PCR increased to 35.5% for the cytology laboratory (range, 13%–42.6% per CP). Comparison analysis indicates a combination of overcalling benign cases and, less frequently, undercalling of higher TBSRTC category cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The AUS rate in the context of PCR is a useful metric to assess cytology laboratory and cytopathologists’ performance. Continuous feedback on this metric could help improve the overall quality of reporting thyroid cytology.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 8","pages":"481-490"},"PeriodicalIF":2.6,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22821","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140570161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spotlight: Rising stars in cytology 聚焦:细胞学新星
IF 3.4 3区 医学
Cancer Cytopathology Pub Date : 2024-04-09 DOI: 10.1002/cncy.22813
Jaylou M. Velez Torres MD, FCAP
{"title":"Spotlight: Rising stars in cytology","authors":"Jaylou M. Velez Torres MD, FCAP","doi":"10.1002/cncy.22813","DOIUrl":"10.1002/cncy.22813","url":null,"abstract":"","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 6","pages":"333-334"},"PeriodicalIF":3.4,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140570110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信